Ventripoint Diagnostics Ltd: VENTRIPOINT EXPANDS EUROPEAN NETWORK OF EXPERT USERS TO INCLUDE MAJOR CARDIAC CENTRES IN AUSTRIA, NETHERLANDS AND GERMANY
DGAP-News: Ventripoint Diagnostics Ltd / Schlagwort(e): Strategische
Unternehmensentscheidung/Vertrag
Ventripoint Diagnostics Ltd: VENTRIPOINT EXPANDS EUROPEAN NETWORK OF
EXPERT USERS TO INCLUDE MAJOR CARDIAC CENTRES IN AUSTRIA, NETHERLANDS
AND GERMANY
23.11.2012 / 08:00
---------------------------------------------------------------------
VENTRIPOINT EXPANDS EUROPEAN NETWORK OF EXPERT USERS TO INCLUDE MAJOR
CARDIAC CENTRES IN AUSTRIA, NETHERLANDS AND GERMANY
Seattle, Washington, November 23, 2012 - VentriPoint Diagnostics (TSXV:
VPT; OTCQX: VPTDF) is excited to announce the installation of its VMS(TM)
heart analysis system in Krankenhaus der Elisabethinen Hospital in Linz,
Austria, University Medical Center Utrecht, The Netherlands and the German
Heart Institute Berlin, Germany.
Prof. Dr. Hans Joachim Nesser, Chief of Cardiology at Linz, and his
colleagues will be studying patients with all forms of Pulmonary
Hypertension and other heart conditions. Dr. Folkert Meijboom of the
University Medical Centre Utrecht will be studying congenital heart disease
patients and Dr. Schmitt at the CHD department in Berlin will be studying
patients with Systemic Right Ventricles and patients with
ventricular-assist devices (VADs).
'The knowledge of cardiovascular diseases has undergone in recent decades
an incredible advancement, especially in the imaging sector. We are
pleased to start using the VMS(TM) at our facility in Linz,' stated Prof
Nesser, 'Thanks to the leadership of Elisabethinen, we have in recent
years, provided a number of pioneering works for the first time in Austria
and so our department has established itself as one of the leaders in the
country.'
'3D imaging has added not only another dimension to imaging, but also in
the understanding of right ventricular function in different states of
diseases that affect the right ventricle. Theoretical considerations on the
relationship between ventricular shape and ventricular function can now be
visualized with the VMS(TM) system, measured and studied and with that,
(hopefully) better understood,' stated Dr. Folkert Meijboom.
'We are continuing to build our European network of expert users by adding
Linz, Utrecht and Berlin to other 7 centres in Europe clinically using the
VMS(TM) heart analysis system.' said Amol Karnick, Vice President, Sales
and Business Development of Ventripoint. 'Germany is an important market
for us and we are pleased to have out first machine in Germany at the
world-renown German Heart Institute in Berlin.'
In other news, Dr. George Adams, the CEO of VentriPoint, will be touring
financial centres in Europe from November 22-20, 2012 and meeting European
institutional investors with Continental Advisors SA to present the company
as an investment opportunity.
About Krankenhaus der Elisabetinen Hospital, Linz, Austria
The Department of Cardiology, Angiography, and Internal Intensive Medicine
at the Elisabethenin Hospital cares for patients with all forms of heart
and vascular diseases with special focus such as poor circulation to the
heart attack, heart valves and heart muscle disease, and patients with
heart failure and arrhythmias. In addition, the Department maintains a
high academic standard by continuous participation in numerous national and
international studies, as well as ongoing cooperation with American centers
such as the University of Chicago and Tufts University in Boston. Numerous
publications in international journals, events of national and
international conferences and symposiums, as well as regular lectures and
department chairs of doctors with special training courses at home and
abroad, complete the picture of this high performance department.
About University Medical Center Utrecht
The University Medical Center Utrecht is one of the largest public
healthcare institutions in the Netherlands. The University Medical Center
Utrecht is one of the largest public healthcare institution in the
Netherlands It is one of the 4 centres in The Netherlands for treatment of
congenital heart disease - children and adults. Annualy 300 - 400
operations for congenital heart disease are performed, with excellent
scores in the European registry for surgery in congenital heart disease,
the EACTS. Both in terms of (low) mortality and in complexity the UMCU/WKZ
belongs to the top European centres. It is also one of the 3 centres in the
Netherlands for cardiac transplantation, with special expertise in
ventricular assist devices. Main directions of research of the
cardiovascular research group are 'stem cell therapy' and 'the failing
circulation'. In this category falls the research focus of Dr. Meijboom: 3D
imaging and right ventricular function, in congenital heart disease and
other populations, like arythmogenic RV dysplasia, of which the UMCU has
the largest population in the world, and in pulmonary hypertension. With
an annual budget of ~EUR1B, the hospital performs over 23,000 operations
and has over 300,000 outpatient visits a year.
About German Heart Institute in Berlin
The German Heart Institute Berlin (DHZB) is an internationally renowned
high-performance hospital for the treatment of cardiovascular and thoracic
diseases, for the implantation of mechanical circulatory support systems
and for heart and lung transplantation. Each year more than 6,500
individuals are treated as inpatients and 14,000 outpatients come to the
DHZB for treatment. The DHZB performs about 2,000 diagnostic exams and
more than 1,800 invasive procedures (heart catheterization) are carried out
in patients with congenital and acquired heart disease. The hospital
performs more than 2,500 operations using the heart-lung machine and over
2,000 other operations on the heart. Among these, around 100 operations are
heart and/or lung transplantation and 500 are heart operations in
prematurely born babies, newborns, infants and children.
About VentriPoint Diagnostics Ltd.
VentriPoint has created a diagnostic ultrasound tool to monitor patients
with heart disease, a leading cause of death in developed countries.
VMS(TM) is the first cost-effective and accurate diagnostic tool for
measuring right ventricle heart function. Congenital heart disease in
children and adults and pulmonary arterial Hypertension are the first
applications in a suite of applications for all major heart diseases
including cardiovascular disease and heart failure - a multi-billion dollar
market potential. Canada and Europe (CE Mark) have granted approval for the
sale of its VMS(TM) diagnostic tool and the company is pursuing the US-FDA
marketing clearance through the 510(k) process.
For further information, please contact:
VentriPoint Diagnostics Ltd.
Dr. George Adams, CEO
Telephone: (206) 283-0221, ext. 401
email: gadams@ventripoint.com
www.ventripoint.com
FORWARD-LOOKING STATEMENTS: The statements made in this press release that
are not historical facts contain forward-looking information that involves
risk and uncertainties. All statements, other than statements of historical
facts, which address VentriPoint's expectations, should be considered
forward-looking statements. Such statements are based on management's
exercise of business judgment as well as assumptions made by and
information currently available to management. When used in this document,
the words 'may', 'will', 'anticipate', 'believe', 'estimate', 'expect',
'intend' and words of similar import, are intended to identify any
forward-looking statements. You should not place undue reliance on these
forward-looking statements. These statements reflect a current view of
future events and are subject to certain risks and uncertainties as
contained in the Corporation's filings with Canadian securities regulatory
authorities. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual
results could differ materially from those anticipated in these
forward-looking statements. The Corporation undertakes no obligation, and
does not intend, to update, revise or otherwise publicly release any
revisions to these forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of any
unanticipated events. Although management believes that expectations are
based on reasonable assumptions, no assurance can be given that these
expectations will materialize.
Ende der Corporate News
---------------------------------------------------------------------
23.11.2012 Veröffentlichung einer Corporate News/Finanznachricht,
übermittelt durch die DGAP - ein Unternehmen der EquityStory AG.
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber
verantwortlich.
Die DGAP Distributionsservices umfassen gesetzliche Meldepflichten,
Corporate News/Finanznachrichten und Pressemitteilungen.
Medienarchiv unter http://www.dgap-medientreff.de und
http://www.dgap.de
---------------------------------------------------------------------
194413 23.11.2012
DGAP-News: Ventripoint Diagnostics Ltd / Schlagwort(e): Strategische
Unternehmensentscheidung/Vertrag
Ventripoint Diagnostics Ltd: VENTRIPOINT EXPANDS EUROPEAN NETWORK OF
EXPERT USERS TO INCLUDE MAJOR CARDIAC CENTRES IN AUSTRIA, NETHERLANDS
AND GERMANY
23.11.2012 / 08:00
---------------------------------------------------------------------
VENTRIPOINT EXPANDS EUROPEAN NETWORK OF EXPERT USERS TO INCLUDE MAJOR
CARDIAC CENTRES IN AUSTRIA, NETHERLANDS AND GERMANY
Seattle, Washington, November 23, 2012 - VentriPoint Diagnostics (TSXV:
VPT; OTCQX: VPTDF) is excited to announce the installation of its VMS(TM)
heart analysis system in Krankenhaus der Elisabethinen Hospital in Linz,
Austria, University Medical Center Utrecht, The Netherlands and the German
Heart Institute Berlin, Germany.
Prof. Dr. Hans Joachim Nesser, Chief of Cardiology at Linz, and his
colleagues will be studying patients with all forms of Pulmonary
Hypertension and other heart conditions. Dr. Folkert Meijboom of the
University Medical Centre Utrecht will be studying congenital heart disease
patients and Dr. Schmitt at the CHD department in Berlin will be studying
patients with Systemic Right Ventricles and patients with
ventricular-assist devices (VADs).
'The knowledge of cardiovascular diseases has undergone in recent decades
an incredible advancement, especially in the imaging sector. We are
pleased to start using the VMS(TM) at our facility in Linz,' stated Prof
Nesser, 'Thanks to the leadership of Elisabethinen, we have in recent
years, provided a number of pioneering works for the first time in Austria
and so our department has established itself as one of the leaders in the
country.'
'3D imaging has added not only another dimension to imaging, but also in
the understanding of right ventricular function in different states of
diseases that affect the right ventricle. Theoretical considerations on the
relationship between ventricular shape and ventricular function can now be
visualized with the VMS(TM) system, measured and studied and with that,
(hopefully) better understood,' stated Dr. Folkert Meijboom.
'We are continuing to build our European network of expert users by adding
Linz, Utrecht and Berlin to other 7 centres in Europe clinically using the
VMS(TM) heart analysis system.' said Amol Karnick, Vice President, Sales
and Business Development of Ventripoint. 'Germany is an important market
for us and we are pleased to have out first machine in Germany at the
world-renown German Heart Institute in Berlin.'
In other news, Dr. George Adams, the CEO of VentriPoint, will be touring
financial centres in Europe from November 22-20, 2012 and meeting European
institutional investors with Continental Advisors SA to present the company
as an investment opportunity.
About Krankenhaus der Elisabetinen Hospital, Linz, Austria
The Department of Cardiology, Angiography, and Internal Intensive Medicine
at the Elisabethenin Hospital cares for patients with all forms of heart
and vascular diseases with special focus such as poor circulation to the
heart attack, heart valves and heart muscle disease, and patients with
heart failure and arrhythmias. In addition, the Department maintains a
high academic standard by continuous participation in numerous national and
international studies, as well as ongoing cooperation with American centers
such as the University of Chicago and Tufts University in Boston. Numerous
publications in international journals, events of national and
international conferences and symposiums, as well as regular lectures and
department chairs of doctors with special training courses at home and
abroad, complete the picture of this high performance department.
About University Medical Center Utrecht
The University Medical Center Utrecht is one of the largest public
healthcare institutions in the Netherlands. The University Medical Center
Utrecht is one of the largest public healthcare institution in the
Netherlands It is one of the 4 centres in The Netherlands for treatment of
congenital heart disease - children and adults. Annualy 300 - 400
operations for congenital heart disease are performed, with excellent
scores in the European registry for surgery in congenital heart disease,
the EACTS. Both in terms of (low) mortality and in complexity the UMCU/WKZ
belongs to the top European centres. It is also one of the 3 centres in the
Netherlands for cardiac transplantation, with special expertise in
ventricular assist devices. Main directions of research of the
cardiovascular research group are 'stem cell therapy' and 'the failing
circulation'. In this category falls the research focus of Dr. Meijboom: 3D
imaging and right ventricular function, in congenital heart disease and
other populations, like arythmogenic RV dysplasia, of which the UMCU has
the largest population in the world, and in pulmonary hypertension. With
an annual budget of ~EUR1B, the hospital performs over 23,000 operations
and has over 300,000 outpatient visits a year.
About German Heart Institute in Berlin
The German Heart Institute Berlin (DHZB) is an internationally renowned
high-performance hospital for the treatment of cardiovascular and thoracic
diseases, for the implantation of mechanical circulatory support systems
and for heart and lung transplantation. Each year more than 6,500
individuals are treated as inpatients and 14,000 outpatients come to the
DHZB for treatment. The DHZB performs about 2,000 diagnostic exams and
more than 1,800 invasive procedures (heart catheterization) are carried out
in patients with congenital and acquired heart disease. The hospital
performs more than 2,500 operations using the heart-lung machine and over
2,000 other operations on the heart. Among these, around 100 operations are
heart and/or lung transplantation and 500 are heart operations in
prematurely born babies, newborns, infants and children.
About VentriPoint Diagnostics Ltd.
VentriPoint has created a diagnostic ultrasound tool to monitor patients
with heart disease, a leading cause of death in developed countries.
VMS(TM) is the first cost-effective and accurate diagnostic tool for
measuring right ventricle heart function. Congenital heart disease in
children and adults and pulmonary arterial Hypertension are the first
applications in a suite of applications for all major heart diseases
including cardiovascular disease and heart failure - a multi-billion dollar
market potential. Canada and Europe (CE Mark) have granted approval for the
sale of its VMS(TM) diagnostic tool and the company is pursuing the US-FDA
marketing clearance through the 510(k) process.
For further information, please contact:
VentriPoint Diagnostics Ltd.
Dr. George Adams, CEO
Telephone: (206) 283-0221, ext. 401
email: gadams@ventripoint.com
www.ventripoint.com
FORWARD-LOOKING STATEMENTS: The statements made in this press release that
are not historical facts contain forward-looking information that involves
risk and uncertainties. All statements, other than statements of historical
facts, which address VentriPoint's expectations, should be considered
forward-looking statements. Such statements are based on management's
exercise of business judgment as well as assumptions made by and
information currently available to management. When used in this document,
the words 'may', 'will', 'anticipate', 'believe', 'estimate', 'expect',
'intend' and words of similar import, are intended to identify any
forward-looking statements. You should not place undue reliance on these
forward-looking statements. These statements reflect a current view of
future events and are subject to certain risks and uncertainties as
contained in the Corporation's filings with Canadian securities regulatory
authorities. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual
results could differ materially from those anticipated in these
forward-looking statements. The Corporation undertakes no obligation, and
does not intend, to update, revise or otherwise publicly release any
revisions to these forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of any
unanticipated events. Although management believes that expectations are
based on reasonable assumptions, no assurance can be given that these
expectations will materialize.
Ende der Corporate News
---------------------------------------------------------------------
23.11.2012 Veröffentlichung einer Corporate News/Finanznachricht,
übermittelt durch die DGAP - ein Unternehmen der EquityStory AG.
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber
verantwortlich.
Die DGAP Distributionsservices umfassen gesetzliche Meldepflichten,
Corporate News/Finanznachrichten und Pressemitteilungen.
Medienarchiv unter http://www.dgap-medientreff.de und
http://www.dgap.de
---------------------------------------------------------------------
194413 23.11.2012